NCI and all five cooperative groups that make up the National Clinical Trials Network have launched a large-scale precision medicine initiative that will match cancer patients with early-phase clinical trials testing novel drug combinations that target specific tumor alterations.
The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.
